Jan, 2023, Simnotrelvir Tablets/Ritonavir Tablets (co-packaged) submitted by Hainan Simcere Pharmaceutical Co., Ltd. received special drug approval as class 1 innovative drug for emergency application at China National Medical Products Administration (NMPA) with conditional requirements.
Simnotrelvir Tablets/Ritonavir Tablets (Brand name: XIANNUOXIN) It is an oral small molecule drug for treatment of mild to moderate COVID-19 infection for adult. Patients should use the medicine strictly according to the instructions under the guidance of doctors.
What is the mechanism of Simnotrelvir Tablets/Ritonavir Tablets? According to the research, 3CL protease is exactly the enzyme necessary for the replication of SARS-CoV-2, which causes the new crown epidemic. Simnotrelvir targets 3CL protease that is essential for SARS-CoV-2 viral replication. A combination with low-dose ritonavir can help slow simnotrelvir being metabolized or divided in human bodies and thus improve anti-COVID-19 effect.[1]https://www.simcere.com/en/news/detail.aspx?mtt=315
Simnotrelvir Tablets/Ritonavir Tablets is the first 3CL anti-COVID-19 drug in China with patients, the approval will brings more choices for COVID-19 treatment in China. NPMA requires MA holders to continue relevant research work, complete conditional requirements within a specified time limit, and submit subsequent research results timely
References
| ↑1 | https://www.simcere.com/en/news/detail.aspx?mtt=315 |
